Identification of targetable oncogenes using histopathological approaches
| Project/Area Number |
25250020
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | Japanese Foundation for Cancer Research |
|---|
Principal Investigator |
TAKEUCHI KENGO 公益財団法人がん研究会, 分子標的病理プロジェクト, 研究員 (40323612)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥44,590,000 (Direct Cost: ¥34,300,000、Indirect Cost: ¥10,290,000)
Fiscal Year 2015: ¥13,390,000 (Direct Cost: ¥10,300,000、Indirect Cost: ¥3,090,000)
Fiscal Year 2014: ¥13,390,000 (Direct Cost: ¥10,300,000、Indirect Cost: ¥3,090,000)
Fiscal Year 2013: ¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
|
|---|
| Keywords | チロシンキナーゼ / 融合遺伝子 |
|---|
| Outline of Final Research Achievements |
During the study period, more than 100,000 FISH screenings were performed in lung cancer, gynecological cancer, breast cancer, colon cancer, pancreatic cancer, head and neck cancer, and lymphoma. Several fusion genes were identified (unpublished) in gynecological cancer, colon cancer, pancreatic cancer and head and neck cancer and lymphoma.
Genetic abnormalities were comprehensively examined and reported in various lymphomas. Transgenic mice simulating ROS1-positive lung cancer was developed and reported with the results of experiments using ROS1 inhibitors. Novel resistant mechanisms in ALK-positive lung cancer were reported. Clinical trials using corresponding inhibitors were performed for the patients with RET-positive lung cancer or ALK-positive lung cancer, in which I took charge of a central diagnosis. Several recommendations about the diagnosis of ALK-positive lung cancer were made.
|
Report
(4 results)
Research Products
(42 results)
-
[Journal Article] Mouse models for ROS1-fusion-positive lung cancers and their application to the analysis of multikinase inhibitor efficiency2016
Author(s)
Inoue M, Toki H, Matsui J, Togashi Y, Dobashi A, Fukumura R, Gondo Y, Minowa O, Tanaka N, Mori S, Takeuchi K, Noda T.
-
Journal Title
Carcinogenesis
Volume: in press
Related Report
Peer Reviewed
-
-
[Journal Article] P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.2016
Author(s)
Katayama R*, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, Iafrate AJ, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M*, Fujita N*
-
Journal Title
EBioMedicine
Volume: 3
Pages: 54-66
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant
-
[Journal Article] Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene2016
Author(s)
Kusano H1, Togashi Y, Akiba J, Moriya F, Baba K, Matsuzaki N, Yuba Y, Shiraishi Y, Kanamaru H, Kuroda N, Sakata S, Takeuchi K, Yano H.
-
Journal Title
Am J Surg Pathol
Volume: 40
Issue: 6
Pages: 761-769
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.2016
Author(s)
Sakamoto K, Nakasone H, Togashi Y, Sakata S, Tsuyama N, Baba S, Dobashi A, Asaka R, Tsai CC, Chuang SS, Izutsu K, Kanda Y, Takeuchi K.
-
Journal Title
Int J Hematol
Volume: 103
Issue: 4
Pages: 399-408
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
[Journal Article] Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.2016
Author(s)
Dobashi A, Tsuyama N, Asaka R, Togashi Y, Ueda K, Sakata S, Baba S, Sakamoto K, Hatake K, Takeuchi K.
-
Journal Title
Genes Chromosomes Cancer
Volume: 55
Issue: 5
Pages: 460-471
DOI
Related Report
Peer Reviewed
-
[Journal Article] Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study).2016
Author(s)
Takeuchi K, Togashi Y, Kamihara Y, Fukuyama T, Yoshioka H, Inoue A, Katsuki H, Kiura K, Nakagawa K, Seto T, Maemondo M, Hida T, Harada M, Ohe Y, Nogami N, Yamamoto N, Nishio M, Tamura T.
-
Journal Title
Ann Oncol
Volume: 27
Issue: 1
Pages: 185-192
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Integrated molecular analysis of adult T cell leukemia/lymphoma.2015
Author(s)
Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al.
-
Journal Title
Nat Genet.
Volume: 47(11)
Issue: 11
Pages: 1304-15
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
[Journal Article] Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.2014
Author(s)
Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
-
Journal Title
Clin. Cancer Res.
Volume: 20
Issue: 22
Pages: 5686-5696
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
